Empagliflozin (12.5mg) and Metformin Hydrochloride (500mg): A Powerful Combination for Diabetes Management

Introduction

GLIEMPAFLOZIN MET 12.5mg/500mg is a combination medication formulated to manage type 2 diabetes mellitus (T2DM) effectively. This oral antidiabetic drug contains Empagliflozin (12.5mg) and Metformin Hydrochloride (500mg), both of which play a crucial role in maintaining optimal blood glucose levels.

With the growing prevalence of diabetes worldwide, GLIEMPAFLOZIN MET 12.5mg/500mg offers a promising solution for those struggling with high blood sugar levels by addressing different aspects of glucose control. This medication improves insulin sensitivity, enhances glucose excretion, and reduces hepatic glucose production, thus helping diabetic patients achieve better glycemic control.

Key Ingredients

Empagliflozin (12.5mg)

Empagliflozin belongs to the sodium-glucose co-transporter 2 (SGLT2) inhibitors class of drugs. It works by blocking glucose reabsorption in the kidneys, leading to increased urinary glucose excretion. This helps lower blood sugar levels while providing additional cardiovascular and renal benefits.

Benefits of Empagliflozin:

• Promotes weight loss by reducing excess glucose in the body.

• Improves glycemic control without causing hypoglycemia.

• Reduces the risk of heart failure and kidney disease in diabetic patients.

• Enhances insulin sensitivity and decreases blood pressure.

Metformin Hydrochloride (500mg)

Metformin Hydrochloride is a biguanide that remains one of the most widely prescribed medications for type 2 diabetes. It works primarily by decreasing hepatic glucose production and increasing peripheral glucose uptake.

Benefits of Metformin Hydrochloride:

• Reduces fasting blood glucose levels effectively.

• Enhances insulin sensitivity in muscle cells.

• Lowers the risk of cardiovascular diseases associated with diabetes.

• Helps in weight management and reduces lipid levels.

How Does Empagliflozin (12.5mg), Metformin Hydrochloride (500mg)?

The combination of Empagliflozin (12.5mg) and Metformin Hydrochloride (500mg) in GLIEMPAFLOZIN MET 12.5mg/500mg provides a dual mechanism to effectively manage type 2 diabetes:

1. Empagliflozin inhibits SGLT2 receptors, preventing glucose reabsorption in the renal tubules and promoting urinary glucose excretion.

2. Metformin Hydrochloride decreases hepatic gluconeogenesis (glucose production in the liver) and improves glucose utilization in peripheral tissues.

3. This combination lowers postprandial glucose levels (after meals) and improves fasting glucose levels.

4. Reduces insulin resistance and promotes a better lipid profile.

Dosage & Administration

• GLIEMPAFLOZIN MET 12.5mg/500mg is typically taken twice daily with meals to minimize gastrointestinal side effects.

• The dosage may be adjusted based on individual response and renal function.

• Patients should follow their doctor’s instructions carefully to achieve the best therapeutic benefits.

Potential Side Effects

Although GLIEMPAFLOZIN MET 12.5mg/500mg is generally well-tolerated, some patients may experience mild to moderate side effects. Common side effects include:

• Frequent urination due to increased glucose excretion.

• Mild dehydration and electrolyte imbalances.

• Gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort.

• Low blood sugar (hypoglycemia) when taken with other antidiabetic drugs.

• Urinary tract infections (UTIs) and genital yeast infections due to higher glucose levels in urine.

• Lactic acidosis (a rare but serious condition) associated with Metformin Hydrochloride.

If any of these side effects persist or worsen, medical attention should be sought immediately.

Precautions & Warnings

Before taking GLIEMPAFLOZIN MET 12.5mg/500mg, patients should consider the following precautions:

• Kidney Function: Regular monitoring of renal function is necessary, as Empagliflozin and Metformin can affect kidney performance.

• Liver Conditions: Patients with hepatic impairment should consult their doctor before taking this medication.

• Dehydration: Increased urination may lead to fluid loss, so patients must stay hydrated.

• Lactic Acidosis Risk: Metformin may cause lactic acidosis in rare cases; patients must report any symptoms of fatigue, muscle pain, or respiratory distress.

• Pregnancy & Breastfeeding: It is not recommended for pregnant or lactating women without medical advice.

• Alcohol Consumption: Alcohol can increase the risk of lactic acidosis and hypoglycemia.

Drug Interactions

GLIEMPAFLOZIN MET 12.5mg/500mg may interact with several medications, including:

• Diuretics: Increased risk of dehydration.

• Insulin or Sulfonylureas: Higher chances of hypoglycemia.

• Beta-blockers: May mask hypoglycemia symptoms.

• ACE inhibitors and ARBs: May affect renal function.

• NSAIDs: Can potentially worsen kidney function when taken with Empagliflozin.

Patients should always inform their healthcare provider about all the medications they are taking to avoid potential drug interactions.

Benefits of Empagliflozin (12.5mg), Metformin Hydrochloride (500mg)

• Enhanced glycemic control through a dual-action mechanism.

• Reduced cardiovascular risk in patients with type 2 diabetes.

• Promotes weight loss while maintaining stable blood sugar levels.

• Lower risk of hypoglycemia compared to insulin or sulfonylureas.

• Improves kidney function and reduces complications related to diabetes-induced nephropathy.

Price and Availability in India

The cost of Empagliflozin (12.5mg), Metformin Hydrochloride (500mg) varies depending on brand, manufacturer, and pharmacy location. On average, a strip of 10 tablets ranges between ₹200 to ₹500 in India. Patients should check with local pharmacies or online medical stores for the best pricing and availability.

Conclusion

GLIEMPAFLOZIN MET 12.5mg/500mg is a highly effective combination therapy for type 2 diabetes, offering multiple benefits in glycemic control, cardiovascular health, and weight management. The combination of Empagliflozin (12.5mg) and Metformin Hydrochloride (500mg) ensures comprehensive diabetes management with minimal risk of hypoglycemia. However, proper medical supervision, lifestyle modifications, and adherence to prescribed dosage are crucial to maximizing the benefits of this medication.

For the best results, patients should consult their healthcare provider before starting GLIEMPAFLOZIN MET 12.5mg/500mg to ensure it aligns with their individual treatment plan and overall health status.

About The Author

STERIS HEALTHCARE PVT LTD

Steris Healthcare Pvt Ltd, known as Sterispharma, was founded in February 2018 by a team of experienced professionals in the pharmaceutical industry. Headquartered in Navi Mumbai, the company holds certifications from WHO, GMP, and ISO, reflecting its dedication to maintaining high standards of quality and safety. Sterispharma’s mission is to provide affordable, high-quality medications across India, strictly adhering to WHO guidelines. With the convenience of an online pharmacy, customers can easily order medicines with home delivery options.

For further information 

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp: 8209542042 , 8824175417

BUY NOW